Abemaciclib: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> | ||
Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.<ref name="a3">PMID:26264704</ref> See also [https://en.wikipedia.org/wiki/Abemaciclib Abemaciclib]. | Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.<ref name="a3">PMID:26264704</ref> See also [https://en.wikipedia.org/wiki/Abemaciclib Abemaciclib] and [[cyclin-dependent kinases]]. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 09:56, 23 October 2023
Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.[1] See also Abemaciclib and cyclin-dependent kinases.
|
| ||||||||||
ReferencesReferences
- ↑ Lu J. Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer. J Hematol Oncol. 2015 Aug 13;8:98. PMID:26264704 doi:10.1186/s13045-015-0194-5